Snapshot from Aug 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Molecular Partners Phase 2 MP0317 Trial
Tech clinical trial update

Molecular Partners Phase 2 MP0317 Trial

Analysis based on 6 articles · First reported Jul 16, 2026 · Last updated Jul 16, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement is a positive but early-stage milestone for Molecular Partners, with no immediate market impact. The stock may see modest interest as the trial progresses, but significant catalysts are years away.

biotechnology pharmaceuticals
Event Summary

Molecular Partners AG announced the dosing of first patients in a Phase 2 proof-of-concept study (TACTIC) of MP0317 in combination with chemoimmunotherapy for first-line treatment of advanced biliary tract carcinoma (cholangiocarcinoma). The randomized, multicenter study in France aims to recruit 75 patients. A data update is expected in 2027, with trial completion in 2028. A trial-in-progress poster has been accepted for presentation at ESMO 2026.

Key Actions
80 Molecular Partners dosed first patients
30 Molecular Partners presented trial-in-progress poster European Society for Medical Oncology
Entities Involved
stock
Molecular Partners
Molecular Partners is the sponsor of the Phase 2 trial; the announcement supports its pipeline progress.
Importance 100.0 Sentiment 10.0
per
Christophe Borg
Principal investigator of the TACTIC study, providing clinical leadership.
Importance 30.0 Sentiment 0.0
per
Philippe Legenne
CMO of Molecular Partners, commenting on the trial's potential.
Importance 20.0 Sentiment 0.0
oth
University Hospital of Besançon
Institution of the principal investigator, involved in the study.
Importance 15.0 Sentiment 0.0
ngo
European Society for Medical Oncology
Conference where the trial-in-progress poster will be presented.
Importance 10.0 Sentiment 0.0
cnt
France
Country where the trial is being conducted.
Importance 10.0 Sentiment 0.0
cnt
United States
Country of Molecular Partners' US office and Nasdaq listing.
Importance 5.0 Sentiment 0.0
exch
Nasdaq
Stock exchange where Molecular Partners is listed.
Importance 5.0 Sentiment 0.0
cnt
Switzerland
Country of Molecular Partners' headquarters.
Importance 5.0 Sentiment 0.0
exch
SIX Swiss Exchange
Stock exchange where Molecular Partners is listed.
Importance 5.0 Sentiment 0.0
Relationships
France strained allies ↔ United States France remains a core NATO ally of the United States but actively opposes Washington's unilateral military actions, part
France related ↔ Switzerland
United States related ↔ Nasdaq
United States related ↔ Switzerland
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.